BioSpace News Archive

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)has recently discussed the use of CAR-T therapies in cancer treatment.

Global HealthTech venture firm Eckuity has announced today that it has invested in Sonrai Analytics, a commercial stage data management and bioinformatics company.

QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy for the treatment of vasomotor symptoms in women taking endocrine therapy for breast cancer, have been published in The Lancet.

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK) today announced that it has presented posters from preclinical studies of four pipeline assets, ATG-031, ATG-101, ATG-018, and ATG-027 at the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022).

Scipher Medicine announced data validating the clinical utility of the company’s PrismRA test for guiding treatment selection for rheumatoid arthritis (RA) patients.

Harbour BioMed (the “Company”, HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDAQ: MRNA), a global biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines.

Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive next-generation liquid biopsy solution that provides genome-wide, genomic and epigenomic insights to capture the mutational landscape and the immune signature of cancer and to help support cancer research and clinical drug development.

J INTS BIO announced on November 9th that it had received approval from the US FDA for its Phase 1/2 clinical trial of its Novel Oral 4th Generation EGFR TKI ‘JIN-A02' in patients with advanced non-small cell lung cancer.

Rallybio Corporation announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of its common stock at a price of $5.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.